Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Tables)

v3.22.2.2
Segment Information (Tables)
3 Months Ended
Sep. 30, 2022
Notes Tables  
Schedule of financial information by reportable segment

The following is financial information relating to the Company's reportable segments (in thousands):

​

​

​

​

​

​

​

​

​

​

Quarter Ended

​

​

September 30, 

​

    

2022

    

2021

Net sales:

 

​

  

​

​

​

Protein Sciences

​

$

199,949

  

$

197,186

Diagnostics and Genomics

​

 

69,904

​

 

60,985

Intersegment

​

 

(198)

​

 

(452)

Consolidated net sales

​

$

269,655

  

$

257,719

​

​

​

​

​

​

​

Operating income:

​

 

  

​

 

  

Protein Sciences

​

$

85,942

  

$

90,100

Diagnostics and Genomics

​

 

8,638

​

 

7,463

Segment operating income

​

$

94,580

​

$

97,563

Costs recognized on sale of acquired inventory

​

 

(300)

​

 

(1,512)

Amortization of acquisition related intangible assets

​

 

(19,283)

​

 

(18,389)

Impact of partially-owned consolidated subsidiaries(1)

​

 

647

​

 

(1,562)

Acquisition related expenses

​

 

(297)

​

 

2,377

Stock based compensation, inclusive of employer taxes

​

 

(15,458)

​

 

(13,860)

Restructuring costs

​

 

(2,170)

​

 

(1,185)

Corporate general, selling, and administrative expenses

​

 

(1,402)

​

 

(210)

Consolidated operating income

​

$

56,317

  

$

63,222

​

(1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party